Determination of Gypenoside A and Gypenoside XLIX in Rat Plasma by UPLC-MS/MS and Applied to the Pharmacokinetics and Bioavailability
International Journal of Analytical Chemistry · 12.08.2022 · 2022 · 1-7
DOI: 10.1155/2022/6734408 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Analytical Chemistry, erschienen am 12.08.2022. Verfasst von Yan He und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wenzhou Medical University.
Abstract (Originalsprache)
In this work, a UPLC-MS/MS method was developed for the determination of gypenoside A and gypenoside XLIX in rat plasma. For chromatographic separation, a UPLC BEH C18 column was employed, the mobile phase comprised acetonitrile: water (w/0.1% formic acid), and the elution time was 4 min. Detection of each compound was enabled by electrospray ionization in negative-ion mode, and quantitative analysis was enabled by operating in multiple reaction monitoring (MRM) mode by monitoring the transitions of m/z 897.5⟶403.3 for gypenoside A, m/z 1045.5⟶118.9 for gypenoside XLIX, and m/z 825.4⟶617.5 for the internal standard. The calibration curves for gypenoside A and gypenoside XLIX demonstrated excellent linearity (r > 0.995) over the range of 2–3000 ng/mL. The intraday and interday precisions of gypenoside A and gypenoside XLIX were within 14.9%, the intraday and interday accuracies ranged from 90.1% to 113.9%, the recoveries were all greater than 88.3%, and the matrix effect ranged from 87.1% to 94.1%. The developed method was successfully applied in the determination of the pharmacokinetics of gypenoside A and gypenoside XLIX. Gypenoside A and gypenoside XLIX had very short half-lives in rats, with oral t1/2z of 1.4 ± 0.2 h and 1.8 ± 0.6 h, respectively, and low bioavailabilities (0.90% and 0.14%, respectively).
Autor:innen und Institutionen
- The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.
- Laboratory Animal Center, Wenzhou Medical University, Wenzhou, China.
- Analytical and Testing Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Congcong Wen
Förderung
- Wenzhou Medical University
Zitieren
APA
He, Y., Liang, Q., Luo, L., He, Y., Huang, X., & Wen, C. (2022). Determination of Gypenoside A and Gypenoside XLIX in Rat Plasma by UPLC-MS/MS and Applied to the Pharmacokinetics and Bioavailability. International Journal of Analytical Chemistry, 2022, 1-7. https://doi.org/10.1155/2022/6734408
Vancouver
He Y, Liang Q, Luo L, He Y, Huang X, Wen C. Determination of Gypenoside A and Gypenoside XLIX in Rat Plasma by UPLC-MS/MS and Applied to the Pharmacokinetics and Bioavailability. International Journal of Analytical Chemistry. 2022;2022:1-7. doi:10.1155/2022/6734408
BibTeX
@article{He2022,
author = {He, Yan and Liang, Qishun and Luo, Lvqi and He, Yifan and Huang, Xueli and Wen, Congcong},
title = {Determination of Gypenoside A and Gypenoside XLIX in Rat Plasma by UPLC-MS/MS and Applied to the Pharmacokinetics and Bioavailability},
journal = {International Journal of Analytical Chemistry},
year = {2022},
volume = {2022},
pages = {1--7},
doi = {10.1155/2022/6734408}
}
EUVIMED